NCT04667975 - The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 21, 2020

Primary Completion Date

August 15, 2021

Study Completion Date

August 30, 2024

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

CKD-702

In principle, based on 1 cycle of 28 days (4 weeks), administer CKD-702 Inj. once every 2 weeks over 4 weeks.

Trial Locations (1)

RECRUITING

Seoul National University Hospital, Seoul